BioSpace News Archive

SALT LAKE CITY, May 9, 2019 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the EndoPredict® test (EPclin) identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis.

Aiming to simplify and speed up complicated radiology workflows, NVIDIA and King’s College London today announced they are partnering to build an AI platform that will in the near future allow specialists in the U.K.’s National Health Service (NHS) to train computers to automate the most time-consuming part of radiology interpretation.

In the recently published 2018 annual report, Watson-Marlow Fluid Technology Group (WMFTG), a Spirax-Sarco Engineering Company, reported excellent sales of over £265 million, driven by the continued growth of key industries as well as aggressive overseas expansion.

IMV Inc. released its financial and operational results for the first quarter ended March 31, 2019.

Donation Provides up to 2.4 Million Free Bottles Annually to Uninsured Americans at Risk for HIV

Company Presents 17 Abstracts Highlighting Commitment to Improving Patient Outcomes and Promise of Remote Monitoring for Home Dialysis Patients

The California Pharmacists Association is pleased to announce that Rajan Vaidya, PharmD has joined the organization in the CPhA Center for Advocacy, the government affairs and public policy unit of the association.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, has announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions, as detailed in the company press release.

Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, announced today that Laura Helms Reece, DrPH and co-CEO of the company, was named a CEO of the Year by the Triangle Business Journal.

Oncoceutics announced that the US Food and Drug Administration invited the company to present information regarding its lead compound ONC201 at the public advisory committee meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on June 20, 2019.